{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', \"IRO REC'D MAR 04 2021\", 'Drug Substance', 'Olaparib (AZD2281, KU-', '0059436); Testosterone', 'Consortium Study', '9984', 'Number', 'Version Number', '1.6', 'Date', 'February 24, 2021', 'Bipolar Androgen Therapy Plus Olaparib in Patient with Castration-', 'Resistant Prostate Cancer', 'Financial and Medication Support: AstraZeneca', 'Principal Investigator: Michael T. Schweizer, MD', 'FHCRC IRB Approval', 'MAR 25 2021', 'Document Released Date', '1(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'TABLE OF CONTENTS', 'PAGE', 'TITLE PAGE', '1', 'TABLE OF CONTENTS', '2', '1. INTRODUCTION', '10', '1.1', 'Disease Background', '10', '1.2', 'Supraphysiologic Testosterone (SPT) in CRPC Background', '12', '1.2.1', 'SPT in CRPC Pre-clinical experience', '12', '1.2.2', 'SPT in CRPC Clinical experience', '14', '1.3', 'Olaparib Background', '16', '1.3.1', 'Pre-clinical experience', '17', '1.3.2', 'Toxicology and safety pharmacology summary', '20', '1.3.3', 'Clinical experience', '21', '1.3.3.1', 'Olaparib in mCRPC', '21', '1.3.3.2', 'Emerging Safety Profile', '24', '1.4', 'Research hypothesis', '29', '1.5 Rationale for conducting this study', '29', '1.6 Benefit/risk and ethical assessment', '30', '2.', 'STUDY OBJECTIVES', '31', '2.1', 'Primary objective', '31', '2.2', 'Secondary objectives', '31', '2.3', 'Exploratory objectives', '31', '3.', 'PATIENT SELECTION CRITERIA', '32', '3.1', 'Inclusion criteria', '32', '3.2', 'Exclusion criteria', '33', '4.', 'STUDY PLAN AND PROCEDURES', '36', '4.1', 'Overall study design and flow chart', '36', '4.2', 'Discontinuation of investigational product', '39', '4.2.1', 'Procedures for discontinuation of a subject from investigational product', '39', '4.3', 'Withdrawal from study', '39', '5.', 'TREATMENT ASSESSMENTS AND EVALUATIONS', '40', '5.1', 'Recording of data', '40', '5.2', 'Data collection at enrollment and follow-up', '40', '5.2.1', 'Screening (within 30 days of Cycle 1, Day 1)', '40', '2(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '5.2.2', 'Treatment/Intervention Period', '41', '5.2.3', 'End of study', '42', '5.2.4', 'Follow Up', '43', '5.2.5', 'Long-term Follow Up', '43', '5.3', 'Study calendar', '44', '6.', 'STUDY ASSESSMENTS', '46', '6.1', 'Efficacy', '46', '6.2', 'Safety', '46', '6.2.1', 'Definition of adverse events', '46', '6.2.2', 'Olaparib adverse events of special interest', '46', '6.2.3', 'Assessment of severity', '46', '6.2.4 Definitions of serious adverse event', '47', '6.2.5', 'Assessment of relationship', '48', '6.2.6', 'Early stopping due to adverse events', '45', '6.2.7 Recording of adverse events', '48', '6.2.7.1 Adverse events after the 30 day follow up period', '50', '6.2.8', 'Reporting of serious adverse events', '52', '6.2.9', 'Laboratory safety assessment', '53', '6.2.10', 'Physical examination', '54', '6.2.11', 'ECG', '54', '6.2.12', 'Vital signs', '55', '6.2.12.1', 'Pulse and blood pressure', '55', '6.2.12.2', 'Body temperature', '55', '6.2.13', 'Bone marrow or blood cytogenetic analysis', '55', '6.3', 'Exploratory biomarkers', '55', '6.3.1', 'DNA Damage Repair Gene Status', '55', '6.3.2', 'Protein expression studies', '56', '6.3.3', 'Transcript profiling studies', '56', '6.3.4', 'Tissue and Serum Androgen Levels', '56', '6.4', 'Patient reported outcomes (PRO)', '56', '7.', 'BIOLOGICAL SAMPLING PROCEDURES', '57', '7.1', 'Volume of blood', '57', '7.2 Handling, storage and destruction of biological samples', '57', '8.', 'STUDY CONDUCT', '58', '8.1', 'Restrictions during the study', '58', '8.1.1', 'Grapefruit juice', '58', '8.1.2', 'Contraception', '58', '8.2', 'Treatments', '58', '8.2.1', 'Identity of investigational product(s)', '58', '8.2.2', 'Olaparib doses and treatment regimens', '58', '3(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}